CTLA4 and melanoma: (2) Tremelimumab. A CTLA-4 blocking Ig G2 monoclonal antibody showed durable responses in advanced melanoma patients in early phase studies; however in phase III trial at dose of 15 mg/kg versus standard chemotherapy, Tremelimumab showed no survival benefits.